Waters New Bioseparations Tools Accelerate and Improve Development of RNA-based Vaccines and Therapies Using LC-MS Analysis

Waters Corporation California

on Oct. 16 at 11:00am ETJoin Waters at the PharmSci 360 conference for an expert session on "Oligo Mapping of Large RNA Therapeutics by Novel Enzyme Specificities" with Dr. Bala Addepalli, Waters Director, R&D New Modalities Portfolio on Oct. 21, at 11:00am ETFollow and connect with Waters via LinkedIn, Twitter, and Facebook

About Waters Corporation (www.waters.com)

Waters Corporation (NYSE: WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 65 years. With approximately 7,500 employees worldwide, Waters operates directly in 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries.

Waters, Rapizyme, IonHance, and waters_connect are trademarks of Waters Technologies Corporation.

Contact:
Janice Foley
Senior Public Relations Manager, Corporate Communications
Waters Corporation
[e-mail]
+1.617.823.5555

i 100% RNA sequence coverage achieved for HPRT sgRNA digested with RapiZyme MC1 and RapiZyme Cusativin compared to traditional digestion methods such as RNase T1. Waters Application Note 720008539EN: "Tunable Digestions of RNA Using RapiZyme RNases to Confirm Sequence and Map Modifications" .

ii IonHance HFIP reagents are certified to contain less than 100 ppb sodium and less than 100 ppb potassium content, resulting in reduced adduct formation and improved sensitivity of RNA detection compared to commercially available HFIP. Waters Application Note 720008540EN: "Evaluating IonHance Hexafluoroisopropanol (HFIP) for Enhanced LC-MS Oligonucleotide Analysis"

iii Waters RapiZyme RNase protocol simplifies sample preparation with three steps including reagent preparation, RNA digestion, and heat inactivation without the need to add chemical denaturants and enzyme inhibitors.

View original content:https://www.prnewswire.co.uk/news-releases/waters-new-bioseparations-tools-accelerate-and-improve-development-of-rna-based-vaccines-and-therapies-using-lc-ms-analysis-302272407.html